Mind Medicine (MindMed) Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG00F13HYQ7
MNMD
Mind Medicine (MindMed) Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
Mind Medicine (MindMed) Inc.
ISIN
CA60255C8850
TICKER
MNMD
MIC
XNAS
REUTERS
MNMD.OQ
BLOOMBERG
MNMD US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Thu, 19.12.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024.
“2024 has been a transform...
Mind Medicine
Mon, 16.12.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) fo...
Mind Medicine
Wed, 11.12.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized ...
Mind Medicine
Thu, 05.12.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatme...
Mind Medicine
Tue, 03.12.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive ...
Mind Medicine
Mon, 02.12.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 171,000 common shar...
Mind Medicine
Mon, 18.11.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Com...
Mind Medicine
Wed, 13.11.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:
Jefferies London Healthcare Conference
F...
Mind Medicine
Thu, 07.11.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended September 30, 2024, and provided a business update.
“This is a pivotal moment for MindMed as we prepa...
Mind Medicine
Thu, 24.10.2024
Mind Medicine
CA60255C8850
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s resul...
Mind Medicine
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
